uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Go back to uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC| UNIQURE (NASDAQ: QURE) | Delayed: 43.63 +1.44 (3.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $42.19 | 52 Week High | $22.79 | |||
| Open | $43.65 | 52 Week Low | $6.63 | |||
| Day High | $44.99 | P/E | N/A | |||
| Day Low | $43.00 | EPS | $0.00 | |||
| Volume | 1,695,194 | |||||
